Background: Responsible innovation in health (RIH) emphasizes the importance of developing technologies that are responsive to system-level challenges and support equitable and sustainable healthcare. To help decision-makers identify whether an innovation fulfills RIH requirements, we developed and validated an evidence-informed assessment tool comprised of 4 inclusion and exclusion criteria, 9 assessment attributes and a scoring system.
Methods: We conducted an inter-rater reliability assessment to establish the extent to which 2 raters agree when applying the RIH Tool to a diversified sample of health innovations (n=25). Following the Tool's 3-step process, sources of information were collected and cross-checked to ensure their clarity and relevance. Ratings were reported independently in a spreadsheet to generate the study's database. To measure inter-rater reliability, we used: a non-adjusted index (percent agreement), a chance-adjusted index (Gwet's AC) and the Pearson's correlation coefficient. Results of the Tool's application to the whole sample of innovations are summarized through descriptive statistics.
Results: Our findings show complete agreement for the screening criteria, "almost perfect" agreement for 7 assessment attributes, "substantial" agreement for 2 attributes and "almost perfect" agreement for the RIH overall score. A large portion of the sample obtained high scores for 6 attributes (health relevance, health inequalities, responsiveness, level and intensity of care and frugality) and low scores for 3 attributes (ethical, legal, and social issues [ELSIs], inclusiveness and eco-responsibility). At the rating step, 88% of the innovations had a sufficient number of attributes documented (≥ 7/9), but the assessment was based on sources of moderate to high quality (mean score ≥ 2 points) for 36% of the sample. While "Almost all RIH features" were present for 24% of the innovations (RIH mean score between 4.1-5.0 points), "Many RIH features" were present for 52% of the sample (3.1-4.0 points) and "Few RIH features" were present for 24% of the innovations (2.1-3.0 points).
Conclusion: By confirming key aspects of the RIH Tool's reliability and applicability, our study brings its development to completion. It can be jointly put into action by innovation stakeholders who want to foster innovations with greater social, economic and environmental value.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167270 | PMC |
| http://dx.doi.org/10.34172/ijhpm.2020.34 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Minor Phase Morphology on Mechanical and Shape-Memory Properties of Polylactide/Bio-Polyamide Nanocomposite.
Polymers (Basel)
August 2024
Department of Technological and Professional Education, Kryvyi Rih State Pedagogical University, Gagarin av. 54, 50086 Kryvyi Rih, Ukraine.
In situ-generated nanofibrillar polymer-polymer composites are excellent candidates for the production of polymer materials, with high mechanical and SME properties. Their special feature is the high degree of dispersion of the in situ-generated nanofibers and the ability to form entangled nanofiber structures with high aspect ratios through an end-to-end coalescence process, which makes it possible to effectively reinforce the polymer matrix and, in many cases, increase its ductility. The substantial interfacial area, created by the in situ formed fiber/matrix morphology, significantly strengthens the interfacial interactions, which are crucial for shape fixation and shape recovery.
View Article and Find Full Text PDFRebound Intracranial Hypertension.
Curr Pain Headache Rep
May 2024
Department of Neurology, Jefferson Headache Center, Thomas Jefferson University Hospitals, Philadelphia, PA, USA.
Purpose Of Review: Rebound intracranial hypertension (RIH) is a post-procedural treatment complication in patients with spontaneous intracranial hypotension (SIH) characterized by transient high-pressure headache symptoms. This article reviews the epidemiology, clinical features, risk factors, and treatment options for RIH.
Recent Findings: This article discusses how changes in underlying venous pressure and craniospinal elastance can explain symptoms of RIH, idiopathic intracranial hypertension (IIH), and SIH.
Using Generative Modeling to Endow with Potency Initially Inert Compounds with Good Bioavailability and Low Toxicity.
J Chem Inf Model
February 2024
Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom.
In the early stages of drug development, large chemical libraries are typically screened to identify compounds of promising potency against the chosen targets. Often, however, the resulting hit compounds tend to have poor drug metabolism and pharmacokinetics (DMPK), with negative developability features that may be difficult to eliminate. Therefore, starting the drug discovery process with a "null library", compounds that have highly desirable DMPK properties but no potency against the chosen targets, could be advantageous.
View Article and Find Full Text PDFSpinal microRNA-134-5p targets glutamate receptor ionotropic kainate 3 to modulate opioid induced hyperalgesia in mice.
Mol Pain
June 2023
Department of Anesthesiology, Tianjin Research Institute of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China.
Fentanyl and its analogs are extensively used for pain relief. However, their paradoxically pronociceptive effects often lead to increased opioids consumption and risk of chronic pain. Compared to other synthetic opioids, remifentanil has been strongly linked to acute opioid hyperalgesia after exposure [remifentanil-induced hyperalgesia (RIH)].
View Article and Find Full Text PDFExpert Consensus Statement on Proficiency Standards for Dermoscopy Education in Primary Care.
J Am Board Fam Med
February 2023
From the Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston (TT, HQD, KCN); Department of Family Medicine, Maine Medical Center, Portland (PRC, HTA); Department of Family Medicine, Tufts University School of Medicine, Boston, MA (PRC, DRE); Department of Family Medicine, Oregon Health & Science University School of Medicine, Portland (AV, TAJ); Swedish First Hill Family Medicine Residency, Seattle, WA (MDL); Department of Dermatology, Oregon Health & Science University School of Medicine, Portland (EGB, JL, AW); Christus St. Vincent Family Medicine Center, Sante Fe, NM (WB); Department of Dermatology, University Hospital of Zürich, University of Zürich, Zürich, Switzerland (RPB); Cabin Creek Health Systems, Dawes, WV (JMC-L); Lincoln Medical Partners, Damariscotta, ME (VLD); Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA (LKF); Dermatology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium (EH); Institute of Experimental & Clinical Research, Université Catholique de Louvain, Brussels, Belgium (EH); Department of Dermatology, Brigham and Women's Hospital, Boston, MA (RIH); Melanoma Program, Dana-Farber Cancer Institute, Boston, MA (RIH); Veterans Integrated Services Network, Jamaica Plain, MA (RIH); Department of Family Medicine, East Tennessee State University James H. Quillen College of Medicine, Johnson City, TN (JH); Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL (NJ); Sylvester Comprehensive Cancer Center, Miami, FL (NJ); Department of Internal Medicine, Maine Medical Center, Cape Elizabeth, ME (ZK); The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York (TNL, JAS); Department of Telemedicine and Bioinformatics, Jagiellonian University Medical College, Krakow, Poland (JL); Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY (AAM); Simpson DermCare & Family Medicine, Ammon, ID (IS); Department of Family & Community Medicine, University of New Mexico School of Medicine, Albuquerque (DLS); Dermatology Department, King Albert II Cancer and Hematology Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium (IT); Department of Family Medicine, Millinocket Regional Hospital, Millinocket, ME (MJT); Western Maine Primary Care, Norway (MJT); Department of Dermatology & Cutaneous Surgery, Department of Family & Community Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX (RPU); Brigham and Women's Health Care Center, Pembroke, MA (AMW); South Shore Medical Center, Norwell, MA (BLW); Redirect Health, Glendale, AZ (RFW); Department of Family Medicine, University of Washington School of Medicine, Seattle (MLW); Department of Dermatology, University of Kansas Medical Center, Kansas City (DJW); Division of Dermatology, Maine Medical Center, Portland (EVS); Department of Dermatology, Tufts University School of Medicine, Boston, MA (EVS)
Background: Primary care providers (PCPs) frequently address dermatologic concerns and perform skin examinations during clinical encounters. For PCPs who evaluate concerning skin lesions, dermoscopy (a noninvasive skin visualization technique) has been shown to increase the sensitivity for skin cancer diagnosis compared with unassisted clinical examinations. Because no formal consensus existed on the fundamental knowledge and skills that PCPs should have with respect to dermoscopy for skin cancer detection, the objective of this study was to develop an expert consensus statement on proficiency standards for PCPs learning or using dermoscopy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!